Plus Therapeutics, Inc. PSTV
3.87 USD 0.00 (+0.00%)
At closeJul 31, 2026, 4:00 PM EDT
4.18 +0.31 +8.01%
After hours · Jul 31, 4:00 PM ET
3.62 Day range 3.94
52-week range unavailable
- YTD
- -69.65%
- 1 year
- -58.16%
News
globenewswire.com Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment Capital will support continued CNSide® commercial scale-up and development Initial tranche of funding provided at closing with future tranches linked to milestones Forecasted cash runway now into…
globenewswire.com Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines Cerenome highlights SNO/ASCO data showing REYOBIQ CSF distribution and safety, and CNSide's potential to reduce monthly LM treatment costs by up to 47%.
globenewswire.com Cerenome Reports Second Quarter 2026 Financial Results and Business Update HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics,…
globenewswire.com Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered Lives HOUSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), announced today that it has signed an…
defenseworld.net Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives Consensus Recommendation of “Hold” from Brokerages Shares of Plus Therapeutics, Inc. (NASDAQ: PSTV - Get Free Report) have been given a consensus recommendation of "Hold" by the seven analysts that are presently covering the firm, MarketBeat reports.…
globenewswire.com Cerenome Launches as an Integrated CNS Oncology Company HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announces that its corporate rebrand to Cerenome will be completed as scheduled. Effective…
globenewswire.com Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference HOUSTON, July 28, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a healthcare company developing and commercializing targeted therapeutics and diagnostics for…
globenewswire.com Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer HOUSTON, July 21, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or the “Company”), announced today that it has signed…
globenewswire.com Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform Collaboration expected to deliver hundreds of DNA and RNA biomarkers from a single CSF specimen — directly aligned with the updated NCCN Guidelines® (Version 2.2026), which now recognize CSF…
globenewswire.com Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring Updated NCCN language continues to support CSF analysis in the diagnosis and management of leptomeningeal metastases, including CSF cytology follow-up every 4 to 8 weeks for patients receiving…
seekingalpha.com Plus Therapeutics, Inc. (PSTV) Discusses Rebranding and Integrated CNS Oncology Platform Strategy Transcript Plus Therapeutics, Inc. (PSTV) Discusses Rebranding and Integrated CNS Oncology Platform Strategy Transcript
globenewswire.com Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding Plus Therapeutics to become Cerenome, to trade under new Nasdaq ticker CNSY on August 3, 2026 Affirms 2026 guidance on key milestones Reports positive CNSide® commercial progress HOUSTON, June 30,…
globenewswire.com Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer HOUSTON, June 25, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a…
globenewswire.com Plus Therapeutics to Provide Business Update Call on June 30, 2026 Management to update on 2026 mid-year progress, milestones and provide details on its integrated CNS oncology strategy and artificial intelligence plans Management to update on 2026 mid-year…
benzinga.com Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For Monday Top analysts changed their views on top stocks. For all changes, upgrades and downgrades, see analyst ratings page.
proactiveinvestors.com Plus Therapeutics gains CAP accreditation for CNSide CSF assay platform Plus Therapeutics Inc (NASDAQ:PSTV) said its CNSide Diagnostics unit has received accreditation from the College of American Pathologists, a widely recognized standard in laboratory quality, sending…
proactiveinvestors.com Plus Therapeutics gains CAP accreditation for CNSide CSF assay platform Plus Therapeutics Inc (NASDAQ:PSTV) said its CNSide Diagnostics unit has received accreditation from the College of American Pathologists, a widely...
globenewswire.com Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory HOUSTON, June 04, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company advancing…
globenewswire.com Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases Plus and Harvard analysis shows CNSide enables early diagnosis and better clinical decision-making reducing healthcare costs by 40%
globenewswire.com Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology Partnership to deliver a novel AI-native integrated CNS oncology platform Platform will unify and analyze Plus' proprietary therapeutic, diagnostic, and bioinformatics datasets to accelerate…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session 
benzinga.com This Rockwell Automation Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday Top Wall Street analysts changed outlook on top names. Needham downgrades CNTA, Baird downgrades PHR.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com Benzinga Bulls And Bears: TSMC, Rocket Lab, J.B. Hunt — And Space Stocks Soar Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
benzinga.com Crude Oil Gains Over 1%; US Retail Sales Rise 0.6% In November - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Nasdaq Falls Over 100 Points; Bank of America Posts Upbeat Earnings - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Why Gelteq Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket 
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket 
benzinga.com Sify Technologies, Boot Barn Holdings And 3 Stocks To Watch Heading Into Monday US stock futures down, investors focus on Sify, Boot Barn, Wealthfront, Plus Therapeutics, Solowin; Citigroup expected to report Q4 earnings.
benzinga.com Palo Alto To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Friday 
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The market value of their outstanding shares is at $10.5 million.
benzinga.com Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its…
benzinga.com S&P 500 Falls 1%; Accenture Posts Upbeat Earnings U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Thursday. The Dow traded down 0.64% to 45,824.16 while the NASDAQ fell 1.19% to 22,229.54. The S&P…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers PepGen (NASDAQ: PEPG) stock rose 114.3% to $5.7 during Thursday's regular session. The market value of their outstanding shares is at $87.2 million.
benzinga.com Nasdaq Down Over 1%; US Initial Jobless Claims Fall U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 1% on Thursday. Following the market opening Thursday, the Dow traded down 0.50% to 45,889.75 while the NASDAQ fell…- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session. The market value of their outstanding shares is at $87.2 million.
benzinga.com Why Dayforce Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket 
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session 
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session